# Losartan for the Treatment of Pediatric NAFLD

> **NCT03467217** · PHASE2 · TERMINATED · sponsor: **National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)** · enrollment: 83 (actual)

## Conditions studied

- NAFLD - Nonalcoholic Fatty Liver Disease

## Interventions

- **DRUG:** Losartan potassium
- **DRUG:** Placebo losartan capsule

## Key facts

- **NCT ID:** NCT03467217
- **Lead sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-10-02
- **Primary completion:** 2020-06-30
- **Final completion:** 2020-06-30
- **Target enrollment:** 83 (ACTUAL)
- **Why stopped:** Trial stopped for futility
- **Last updated:** 2021-10-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03467217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03467217, "Losartan for the Treatment of Pediatric NAFLD". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03467217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*